228 related articles for article (PubMed ID: 30703770)
21. Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas.
Iwasa S; Morizane C; Okusaka T; Ueno H; Ikeda M; Kondo S; Tanaka T; Nakachi K; Mitsunaga S; Kojima Y; Hagihara A; Hiraoka N
Jpn J Clin Oncol; 2010 Apr; 40(4):313-8. PubMed ID: 20047862
[TBL] [Abstract][Full Text] [Related]
22. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B.
Miller AA; Herndon JE; Hollis DR; Ellerton J; Langleben A; Richards F; Green MR
J Clin Oncol; 1995 Aug; 13(8):1871-9. PubMed ID: 7636529
[TBL] [Abstract][Full Text] [Related]
23. Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms.
Heetfeld M; Chougnet CN; Olsen IH; Rinke A; Borbath I; Crespo G; Barriuso J; Pavel M; O'Toole D; Walter T;
Endocr Relat Cancer; 2015 Aug; 22(4):657-64. PubMed ID: 26113608
[TBL] [Abstract][Full Text] [Related]
24. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
Gillenwater HH; McCune JS; Lindley C; Faucette S; Shord S; Donahue A; Socinski MA; Stewart CF; Zamboni WC; Kirstein MN; Moore D
Cancer Invest; 2005; 23(6):511-9. PubMed ID: 16203659
[TBL] [Abstract][Full Text] [Related]
25. Carboplatin plus oral etoposide in the management of advanced, non-small cell lung cancer: preliminary results of a Vanderbilt trial.
Johnson DH; DeVore R; Greco FA; Walls J; Thomas M; Hande KR; Hainsworth JD
Semin Oncol; 1992 Feb; 19(1 Suppl 2):50-6. PubMed ID: 1329223
[TBL] [Abstract][Full Text] [Related]
26. Activity and safety of oral etoposide in pretreated patients with metastatic or recurrent thymic epithelial tumors (TET): A single-institution experience.
Bluthgen MV; Boutros C; Fayard F; Remon J; Planchard D; Besse B
Lung Cancer; 2016 Sep; 99():111-6. PubMed ID: 27565923
[TBL] [Abstract][Full Text] [Related]
27. Duration: escalation study of oral etoposide with carboplatin in patients with varied solid tumors.
Thiery-Vuillemin A; Dobi E; Nguyen T; Royer B; Montange D; Maurina T; Kalbacher E; Bazan F; Villanueva C; Demarchi M; Chaigneau L; Ivanaj A; Pivot X
Anticancer Drugs; 2010 Nov; 21(10):958-62. PubMed ID: 20856105
[TBL] [Abstract][Full Text] [Related]
28. Carboplatin plus etoposide for extensive stage small-cell lung cancer: an experience with AUC 6 doses of carboplatin.
Yilmaz U; Polat G; Anar C; Halilcolar H
Indian J Cancer; 2011; 48(4):454-9. PubMed ID: 22293260
[TBL] [Abstract][Full Text] [Related]
29. Evaluating bevacizumab in combination with FOLFIRI after the failure of platinum-etoposide regimen in patients with advanced poorly differentiated neuroendocrine carcinoma: The PRODIGE 41-BEVANEC randomized phase II study.
Walter T; Malka D; Hentic O; Lombard-Bohas C; Le Malicot K; Smith D; Ferru A; Assenat E; Cadiot G; Lievre A; Kurtz JE; Dahan L; Dubreuil O; Hautefeuille V; Lepere C; Gangloff A; Elhajbi F; Coriat R; Roquin G; Bouarioua N; Granger V; Scoazec JY; Lepage C
Dig Liver Dis; 2018 Feb; 50(2):195-198. PubMed ID: 29258812
[TBL] [Abstract][Full Text] [Related]
30. [-Intravenous or oral etoposide therapy of platinum refractory ovarian cancer with early recurrence. Results of a prospective randomized study-].
Kuhn W; Schmalfeldt B; Dose J; Pache L; Ulm K; Freitag K; Jänicke F; Graeff H
Geburtshilfe Frauenheilkd; 1996 Feb; 56(2):105-10. PubMed ID: 8647360
[TBL] [Abstract][Full Text] [Related]
31. Dose-escalation study of oral etoposide and carboplatin in patients with advanced lung cancer.
Atagi S; Furuse K; Kawahara M; Kodama N; Ogawara M; Kubota K; Matsui K; Kusunoki Y; Masuda N; Takada M; Negoro S; Fukuoka M
Jpn J Clin Oncol; 1996 Oct; 26(5):316-21. PubMed ID: 8895671
[TBL] [Abstract][Full Text] [Related]
32. Carboplatin-oral etoposide personalized dosing in elderly non-small cell lung cancer patients. Gruppo Oncologico Cooperativo Sud-Italia.
Frasci G; Comella P; Panza N; De Cataldis G; Del Gaizo F; Pozzo C; Gravina A; Ruffolo P; Cioffi R; Marcatili P; Della Vittoria M; Monfardini S; Comella G
Eur J Cancer; 1998 Oct; 34(11):1710-4. PubMed ID: 9893657
[TBL] [Abstract][Full Text] [Related]
33. Treatment of poorly differentiated neuroendocrine carcinoma of the pancreas.
Gupta A; Duque M; Saif MW
JOP; 2013 Jul; 14(4):381-3. PubMed ID: 23846932
[TBL] [Abstract][Full Text] [Related]
34. Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide.
Hainsworth JD; Erland JB; Kalman LA; Schreeder MT; Greco FA
J Clin Oncol; 1997 Jun; 15(6):2385-93. PubMed ID: 9196154
[TBL] [Abstract][Full Text] [Related]
35. A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive-disease small cell lung cancer.
Salgia R; Stille JR; Weaver RW; McCleod M; Hamid O; Polzer J; Roberson S; Flynt A; Spigel DR
Lung Cancer; 2017 Mar; 105():7-13. PubMed ID: 28236984
[TBL] [Abstract][Full Text] [Related]
36. Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma.
Hadoux J; Malka D; Planchard D; Scoazec JY; Caramella C; Guigay J; Boige V; Leboulleux S; Burtin P; Berdelou A; Loriot Y; Duvillard P; Chougnet CN; Déandréis D; Schlumberger M; Borget I; Ducreux M; Baudin E
Endocr Relat Cancer; 2015 Jun; 22(3):289-98. PubMed ID: 25770151
[TBL] [Abstract][Full Text] [Related]
37. Paclitaxel, carboplatin, and oral etoposide in the treatment of small cell lung cancer.
Greco FA; Hainsworth JD
Semin Oncol; 1996 Dec; 23(6 Suppl 16):7-10. PubMed ID: 9007113
[TBL] [Abstract][Full Text] [Related]
38. Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.
Tung N; Berkowitz R; Matulonis U; Quartulli M; Seiden M; Kim Y; Niloff J; Cannistra SA
Gynecol Oncol; 2000 May; 77(2):271-7. PubMed ID: 10785477
[TBL] [Abstract][Full Text] [Related]
39. Topotecan-carboplatin-etoposide combination as 1st line treatment in patients with small cell lung cancer.
Zarogoulidis K; Mylonaki E; Kakavelas P; Zarogoulidis P; Tsiouda T; Rapti E; Lithoxopoulou H; Zarogoulidou V; Kontakiotis T;
Lung Cancer; 2009 Nov; 66(2):226-30. PubMed ID: 19321222
[TBL] [Abstract][Full Text] [Related]
40. Multicentre phase II study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study.
Le Treut J; Sault MC; Lena H; Souquet PJ; Vergnenegre A; Le Caer H; Berard H; Boffa S; Monnet I; Damotte D; Chouaid C
Ann Oncol; 2013 Jun; 24(6):1548-52. PubMed ID: 23406729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]